Re: Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease

dc.contributor.authorOnal, C.
dc.contributor.authorOymak, E.
dc.contributor.authorGuler, O. C.
dc.contributor.pubmedID34973870en_US
dc.date.accessioned2022-11-23T10:23:15Z
dc.date.available2022-11-23T10:23:15Z
dc.date.issued2022
dc.identifier.endpageE172en_US
dc.identifier.issn0936-6555en_US
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85125940404en_US
dc.identifier.startpageE171en_US
dc.identifier.urihttp://hdl.handle.net/11727/8151
dc.identifier.volume34en_US
dc.identifier.wos000768309600005en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.clon.2021.12.013en_US
dc.relation.journalCLINICAL ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleRe: Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Diseaseen_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: